India rejects teneligliptin salts patent
This article was originally published in Scrip
India has rejected Mitsubishi Tanabe's patent application relating to certain salts of teneligliptin, the dipeptidyl peptidase-4 (DPP-4) inhibitor currently in the news after the arrival of a cut-price generic version on the domestic market.
You may also be interested in...
Japan's Mitsubishi Tanabe has moved a court against Indian patent authorities in a case concerning its patent application relating to certain salts of teneligliptin. The move has set the cat among the pigeons in the Indian market, where cut price versions of the diabetes drug have made strong gains over the recent past, though it's still unclear if the salt patent may have a bearing on these.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.